Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages

Journal of Drug Targeting

Volumn 17, Issue 10, 2009, Pages 751-762

  Changsan, Narumon ^a   Nilkaeo, Athip ^a   Pungrassami, Pethchawan ^b   Srichana, Teerapol ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b Zonal Tuberculosis Center 12th   (Thailand)

Author keywords

Liposomes; M cell; Targeted drug delivery; Tuberculosis

Indexed keywords

INTERLEUKIN 1BETA; LIPOSOME; NITRIC OXIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRY POWDER; ENCAPSULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MASS MEDIUM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CELL LINE; CRYOPROTECTIVE AGENTS; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; FREEZE DRYING; HUMANS; LIPOSOMES; MACROPHAGES, ALVEOLAR; MANNITOL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; PARTICLE SIZE; POWDERS; RATS; RIFAMPIN;

EID: 70350784057     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903079462     Document Type: Article

References (39)

1. Ahsan F, Rivas IP, Khan MA, Suárez AIT. (2002). Targeting to macrophage: Role of physicochemical properties of particulate carriers-liposome and microspheres-on the phagocytosis by macrophages. J Control Release, 79, 29-40.
2. American Lecithin Company. (2002). Learn about lecithin: A simple guide to use and selection. Last accessed at http:// americanlecithin.com
3. American Type Cell Culture. (2008). Last accessed at www.atcc.org
4. Azarmi S, Roa WH, Löbenberg R. (2008). Targeted delivery of nanoparticles for the treatment of lung disease. Adv Drug Deliv Rev, 60, 863-875.
5. Barrow ELW, Winchester GA, Stass JK, Quenelle DC, Barrow WW. (1998). Use of microsphere technology of targeted delivery of rifampicin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother, 42, 2682-2689.
6. Calleri E, Lorenzi ED, Furlanetto S, Massolini G, Caccialanza G. (2002). Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation. J Pharm Biomed Anal, 29, 1089-1096.
7. Challoner PB. (2002). Aerosol delivery of antibiotics. In Plattner JJ, ed. Annual Reports in Medicinal Chemistry (pp. 149-158). New York: Elsevier Science.
8. Changsan N, Chan H-K, Separovic F, Srichana T. (2009). Rifampicin liposome dry powder formulations for inhalation. J Pharm Sci, 98, 628-639.
9. Collins DM. (2001). Virulence factors of Mycobacterium bovis. Tuberculosis, 81, 97-102.
10. Cosgrove B, Cheng C, Pritchard J, Stolz D, Lauffenburger D, Griffith L. (2008). An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factoralpha. Hepatology, 48, 276-288.
11. Deol P, Khuller GK, Joshi K. (1997). Therapeutic efficacies of isoniazid and rifampicin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother, 41, 1211-1214.
12. Frederik PM, Hubert DHW. (2005). Cryoelectron microscopy of liposomes. Methods Enzymol, 391, 431-448.
13. Frieden TR, Stering TR, Munstiff SS, Watt CJ, Dye C. (2003). Tuberculosis. Lancet, 362, 887-899.
14. Fujiwara PI, Simone PM, Munsiff SS. (2000). Treatment of tuberculosis. In Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach (pp. 401-446.). New York: Marcel Dekker, Inc.
15. Gilbert BE, Knight C, Alvarez FG, Waldrep JC, Rodarte JR, Knight V, Enchenbacher WL. (1997). Tolerance of volunteer to cyclosporine A-dilauroylphosphati-dylchoine liposome aerosol. Am J Respir Crit Care Med, 156, 1789-1793. (Pubitemid 28011783)
16. Hickey AJ, Jones LTD. (2000). Particle-size analysis of pharmaceutical aerosols. Pharm Technol, 9, 48-58.
17. Huttunen K, Ruotsalainen M, Iivanainen E, Torkko P, Katila ML, Hirvonen MR. (2000). Inflammatory responses in RAW 264.7 macrophages caused by mycobacteria isolated from moldy houses. Environ Toxicol Pharmacol, 8, 237-244.
18. Malvern Instrument Ltd. (2005). Zeta potential theory. In Zetasizer Nano Series User Manual (pp. 16.1-16.12). Malvern, UK: Malvern Instrument Ltd.
19. McCalden TA. (1990). Particulate systems for drug delivery to the lung. Adv Drug Deliv Rev, 5, 253-263.
20. Mehta RT, Keyhani A, McQueen TJ, Rosenbaum B, Rolston KV, Tarrand JT. (1993). In vitro activities of free and liposomal drugs against Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother, 37, 2584-2587.
21. Ng KY, Stringer KA, Cohen Z, Serravo R, Tian B, Meyer JD, Falk R, Randolp T, Manning MC, Thompson DC. (1998). Alveolar macrophage is not activated by exposure to polymeric microspheres. Int J Pharm, 179, 41-49.
22. Palmer SM, Drew RH, Whitehouse JD, Tapson VF, Davis RD, McConnell RR, Kanj SS, Perfect JR. (2001). Safety of aerosolized amphotericin B lipid complex in lung transplant recipient. Transplantation, 72, 545-548.
23. Punturee K, Wild CP, Vinitketkumneun U. (2004). Thai medicinal plant modulate nitric oxide and tumor necrosis factor in J774.2 mouse macrophage. J Ethnopharmacol, 95, 183-189.
24. Ritelli M, Amadori M, Tagliabue S, Pacciarini ML. (2003). Use of a macrophage cell line for rapid detection of Mycobacterium bovis in diagnostic samples. Veter Microbiol, 94, 105-120.
25. Rodrigues C, Gameiro P, Prieto M, Castro B. (2003). Interaction of rifampicin and isoniazid with large unilamellar liposomes: Spectroscopic location studies. Biochim Biophys Acta, 1620, 151-159.
26. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. (1993). Pulmonary delivery of liposomes. J Control Release, 24, 209-223.
27. Sharma R, Saxena D, Dwivedi A, Missa A. (2001). Inhalable microparticles containing drug combinations to target alveolar macrophage for treatment of pulmonary tuberculosis. Pharm Res, 18, 1405-1410.
28. Srichana T, Martin GP, Marriott C. (1998). On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm, 167, 13-23.
29. Srichana T, Suedee R, Srisudjai P. (2003). Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie, 58, 125-129.
30. Ten RM, Anderson, PM, Zein NN, Temesgen Z, Clawson ML, Weiss W. (2002). Interleukin-2 liposomes for primary immune deficiency. Int Immunopharmacol, 2, 333-344.
31. Thomas DA, Myer MA, Wichert B, Schreier H, Gonzalez-Rothi RJ. (1991). Acute effects of liposome aerosol inhalation on pulmonary function in healthy volunteer. Chest, 99, 1268-1270.
32. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. (1994). Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm, 101, 1-13.
33. Tsurutani J, Sohda H, Oka M, Kohno S. (2000). A case of multidrugresistant pulmonary tuberculosis. Nihon Kokyuki Zasshi, 8, 594-598.
34. Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, Knight V. (2004). Clinical evaluation of the delivery and safety of aerosolized liposomal 9-Nitro-20(S)-Camptothecin in patients with advanced pulmonary-malignancies. Clin Cancer Res, 10, 2319-2326.
35. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. (2004). Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophage. Int J Pharm, 269, 37-49.
36. Waldrep JC, Gilbert BE, Knight CM, Black MB, Scherer PW, Knight VN, Eschenbacher W. (1997). Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Chest, 111, 316-323.
37. Whitehead TC, Lovering AM, Cropley IM, Wade P, Davidson RN. (1998). Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 17, 794-797.
38. Wilusz R, Weinberg J, Guilak F, McNulty A. (2008). Inhibition of integrative repair of the meniscus following acute exposure to interleukin-1 in vitro. J Orthop Res, 26, 504-512.
39. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. (2007). Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Sci, 67, 655-666.